Spots Global Cancer Trial Database for A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV
Official Title: The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia
Study ID: NCT01809223
Study Description
Brief Summary: This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to pathological myopia.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijing, Beijing, China
Beijing Tongren hospital affiliated to Capital Medical University, Beijing, Beijing, China
Southwest Hospital, Chongqing, Chongqing, China
Daping Hospital, Research Institute of Surgery Third Military Medical University, Chongqing, Chongqing, China
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
Wuhan General Hospital of Guangzhou Military, Wuhan, Hubei, China
Wuxi No.2 People's Hospital, Wuxi, Jiangsu, China
Ophthalmologic Hospital of Qingdao, Qingdao, Shandong, China
Shanghai First People's Hospital, Shanghai, Shanghai, China
Xijing Hospital, Xian, Shanxi, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
The Affiliated Eye Hospital of WMC, Wenzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
